EU parliament could do away with global anti-counterfeit agreement by summer
This article was originally published in SRA
Executive Summary
The controversial Anti-Counterfeiting Trade Agreement, ACTA, aimed at tackling intellectual property rights violations across all sectors, could be dead in the water by the summer if the European Parliament follows the recommendations of its ACTA rapporteur, David Martin. Mr Martin will recommend that the parliament rejects the agreement, which would mean it could not be ratified in the EU1. This could, in turn, influence whether countries outside the EU ratify it, say commentators.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.